{"id":126862,"date":"2022-01-28T06:16:18","date_gmt":"2022-01-28T11:16:18","guid":{"rendered":"https:\/\/44.250.171.167\/?p=126862"},"modified":"2022-01-28T06:20:38","modified_gmt":"2022-01-28T11:20:38","slug":"cipla-limited-cipla-q2-fy22-research-summary","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/cipla-limited-cipla-q2-fy22-research-summary\/","title":{"rendered":"Cipla Limited (CIPLA) Q2 FY22 Research Summary"},"content":{"rendered":"<div>\n<div class=\"\">\n<div id=\"post_ghwoi74bqjfd8pqmrgms1k9qpr\" class=\"a11y__section post same--user same--root  \" tabindex=\"0\" role=\"listitem\" data-testid=\"postView\" aria-label=\"At 3:21 PM Monday, January 24, sreerupam wrote, The pharma giant Cipla's net profit rose 7.57% year-on-year (YoY) to Rs 712 crore for Q2 FY22. Cipla  market research report covers key aspects about the firm, including company profile, financial highlights and key recent developments. The report is meant as a resource for investors to form a 360 degree understanding about the firm.\" aria-atomic=\"true\">\n<div class=\"post__content \" role=\"application\" data-testid=\"postContent\" aria-hidden=\"true\">\n<div>\n<div>\n<div id=\"ghwoi74bqjfd8pqmrgms1k9qpr_message\" class=\"post__body   \">\n<div class=\"post-message post-message--collapsed\">\n<div class=\"post-message__text-container\">\n<div id=\"postMessageText_ghwoi74bqjfd8pqmrgms1k9qpr\" class=\"post-message__text\" dir=\"auto\" tabindex=\"0\" aria-readonly=\"true\">\n<p>The pharma giant <strong><a href=\"https:\/\/44.250.171.167\/symbol\/cipla\/\">Cipla&#8217;s<\/a><\/strong> net profit rose 7.57% year-on-year (YoY) to Rs 712 crore for Q2 FY22. Cipla market research report covers key aspects about the firm, including company profile, financial highlights and key recent developments. The report is meant as a resource for investors to form a 360 degree understanding about the firm.<\/p>\n<p><strong>Table of contents:<\/strong><\/p>\n<ul>\n<li>Company background &amp; history<\/li>\n<li>C-Level Executives<\/li>\n<li>Industry Analysis<\/li>\n<li>Key financial highlights<\/li>\n<li>Competitors<\/li>\n<li>Business segment analysis<\/li>\n<li>SWOT analysis<\/li>\n<li>Key developments<\/li>\n<li>Excerpts from the conference call Q&amp;A<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-white-color has-vivid-green-cyan-background-color has-text-color has-background\" href=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2022\/01\/Cipla-Q2-FY2022-research-summary.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Download CIPLA research summary<\/strong><\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The pharma giant Cipla&#8217;s net profit rose 7.57% year-on-year (YoY) to Rs 712 crore for Q2 FY22. Cipla market research report covers key aspects about the firm, including company profile, financial highlights and key recent developments. The report is meant as a resource for investors to form a 360 degree understanding about the firm. Table [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":58681,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5747,6352],"tags":[8157],"class_list":["post-126862","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare-stocks","category-research-summary","tag-healthcare"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":154517,"url":"https:\/\/alphastreet.com\/india\/ruling-the-therapeutic-medical-segment-ft-cipla\/","url_meta":{"origin":126862,"position":0},"title":"Ruling the Therapeutic Medical Segment Ft Cipla","author":"Chirag Gupta","date":"September 1, 2023","format":false,"excerpt":"Our One-India business continued the double-digit trajectory growing at 12% during the quarter led by branded prescription with sustained growth across chronic therapies. Our continued focus on differentiated portfolio has strengthened our US business which once again posted highest ever quarterly revenue at $ 222 Mn. South Africa Private Market\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":125206,"url":"https:\/\/alphastreet.com\/india\/how-did-cipla-perform-in-q2-2022\/","url_meta":{"origin":126862,"position":1},"title":"How Cipla performed in Q2 2022","author":"Nishadkishore","date":"October 26, 2021","format":false,"excerpt":"The pharma giant Cipla (NSE: CIPL) reported its second-quarter 20223 earnings results on Tuesday after market hours. The total revenue increased by 10.3% to \u20b95,486 crores compared to \u20b94,972 crores in the previous year of the same quarter. The company had a total net profit of \u20b9711 crores or \u20b98.80\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":131066,"url":"https:\/\/alphastreet.com\/india\/cipla-q4-fy2022-research-summary\/","url_meta":{"origin":126862,"position":2},"title":"Cipla Q4 FY2022 Research Summary","author":"sreerupa","date":"July 11, 2022","format":false,"excerpt":"Cipla is an Indian multinational pharmaceutical company. The company was incorporated in the year 1935. The founder is Khwaja Abdul Hamied. Cipla has its headquarters in Mumbai. The company has extended its business worldwide.\u00a0 The presence of this company is marked in Australia, Europe, Kenya, Malaysia, Morocco, Nepal, South Africa,\u2026","rel":"","context":"In &quot;Research Summary&quot;","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"Research Summary","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":126049,"url":"https:\/\/alphastreet.com\/india\/infographic-how-cipla-performed-in-q2-2022\/","url_meta":{"origin":126862,"position":3},"title":"Infographic: How Cipla performed in Q2 2022","author":"Nishad","date":"December 6, 2021","format":false,"excerpt":"Cipla Limited(NSE: CIPLA) posted its second-quarter 2022 results. The company posted consolidated revenue of \u20b95,580 crores with a growth of 9% year on year. Cipla had a net profit of \u20b9709 crores or \u20b98.80 per share compared to \u20b9659 crores or \u20b98.24 per share in the same quarter of the\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/CiplaQ222.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/CiplaQ222.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/CiplaQ222.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/CiplaQ222.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/CiplaQ222.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":169408,"url":"https:\/\/alphastreet.com\/india\/cipla-ltd-q1fy26-10-rise-in-profits\/","url_meta":{"origin":126862,"position":4},"title":"Cipla Ltd Q1 FY26 Earnings Results \u2013 4% Revenue Growth, 10% Rise in Net Profit","author":"Divyansh_Kasana","date":"July 28, 2025","format":false,"excerpt":"Cipla Limited is a leading global pharmaceutical company dedicated to ensuring access to affordable, high-quality medicines across diverse therapeutic segments, including respiratory, anti-retroviral, and chronic care. Headquartered in India and operating in over 80 countries, Cipla continues to advance innovation and patient-centric healthcare. Q1 FY26 Earnings Summary\u00a0(Apr\u2013Jun 2025) Revenue:\u00a0\u20b96,957 crore,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-13.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-13.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-13.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-13.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-13.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-13.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":129444,"url":"https:\/\/alphastreet.com\/india\/cipla-limited-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":126862,"position":5},"title":"Cipla Limited Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 11, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=I-Ubq3MAmzg Key highlights from Cipla Limited (CIPLA) Q4 FY22 Earnings Concall Management Update: CIPLA said it crossed the $1 billion milestone in its domestic-branded prescription business, driven by the sustained growth across the company\u2019s acute and chronic portfolios. Q&A Highlights: Prakash Agarwal from Axis Capital asked about the outlook of\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/126862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=126862"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/126862\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/58681"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=126862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=126862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=126862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}